Press release
Cancer Immunotherapy Market Size to Reach US$ 261.74 Billion by 2033 at 7.9% CAGR
Cancer Immunotherapy Market
Cancer immunotherapy, also known as immuno-oncology, enhances the body's natural immune response to identify and destroy cancer cells. With leading treatments such as immune checkpoint inhibitors, CAR-T cell therapies, monoclonal antibodies, and cancer vaccines, this therapeutic class has revolutionized cancer management and patient survival outcomes.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/cancer-immunotherapy-market?utm_source=OpenPR&utm_campaign=Onkar
Key Highlights from the Report
➤ Global market size to reach US$ 261.74 billion by 2033 with a 7.9% CAGR
➤ Immune checkpoint inhibitors hold the largest market share at 37.5% (2024)
➤ North America leads the market with 57.4% share owing to strong R&D and drug sales
➤ Keytruda (Pembrolizumab) tops global sales, contributing nearly US$ 29.82 billion in 2024
➤ Surge in cancer incidence projected to surpass 29.9 million global cases by 2040 (GLOBOCAN)
➤ Increasing regulatory approvals for new immunotherapies strengthen global market momentum
Market Segmentation
The cancer immunotherapy market is segmented by type, indication, and region.
By type, immune checkpoint inhibitors lead the global market, accounting for 37.5% share in 2024. These drugs block proteins like PD-1, PD-L1, and CTLA-4, preventing cancer cells from evading immune detection. Flagship products such as Keytruda (Merck & Co.), Opdivo (Bristol-Myers Squibb), and Tecentriq (Roche) continue to dominate due to wide-ranging indications and strong clinical outcomes.
Checkpoint inhibitors have redefined cancer therapy, offering long-term remission and higher survival rates across multiple tumor types, including lung, melanoma, breast, and urinary cancers. Ongoing research continues to expand their use for emerging indications and combination therapies.
Regional Insights
North America Dominates the Global Cancer Immunotherapy Market
North America leads with a 57.4% market share in 2024, supported by robust healthcare infrastructure, rapid adoption of innovative treatments, and a high cancer burden. In the U.S., immunotherapy sales generated record revenues, with Keytruda contributing over 60% of its total sales regionally.
The region's strong oncology pipeline and routine integration of immunotherapies into treatment guidelines have further solidified its dominance. Programs by FDA and clinical research consortia have accelerated access to breakthrough therapies for patients across multiple cancer categories.
Asia-Pacific: Fastest Growing Region
The Asia-Pacific region is set to witness the fastest growth rate, owing to rising cancer prevalence, improving healthcare infrastructure, and expanding domestic drug manufacturing capabilities. Increasing government approvals - such as China's NMPA approval of Akeso's Ivonescimab (PD-1/VEGF bispecific antibody) in April 2025 - are improving availability of advanced immunotherapies locally.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/cancer-immunotherapy-market?utm_source=OpenPR&utm_campaign=Onkar
Market Dynamics
Market Drivers
The increasing global incidence of cancer and a strong shift toward targeted therapies are major drivers of market growth. Rising R&D investment and expansion of immunotherapy indications enable early intervention and personalized cancer care.
Market Restraints
High cost remains a critical barrier to widespread adoption. For instance, Merck's Keytruda treatment costs approximately US$ 23,590 per six-week dose, limiting accessibility in low- and middle-income countries despite its proven efficacy.
Market Opportunities
Expanding clinical research, approvals in emerging markets, and combination immunotherapies leveraging AI and biomarker profiling represent strong growth opportunities. Biotech collaborations and adaptive trial designs are expected to accelerate innovation through the forecast period.
Purchase This Exclusive Report at Just USD 4390 Only: https://www.datamintelligence.com/buy-now-page?report=cancer-immunotherapy-market?utm_source=OpenPR&utm_campaign=Onkar
Reasons to Buy the Report
✔ Comprehensive insights into global cancer immunotherapy pipeline trends and growth drivers
✔ Detailed market segmentation by treatment class, indication, and geography
✔ Evaluation of regulatory landscapes shaping access to advanced therapies
✔ Competitive analysis highlighting key players and novel drug approvals
✔ Future market opportunities in emerging economies and next-generation CAR-T therapies
Frequently Asked Questions (FAQs)
◆ How big is the global cancer immunotherapy market in 2024?
◆ Who are the leading companies driving innovation in immuno-oncology?
◆ What are the top-selling immune checkpoint inhibitors globally?
◆ What is the expected CAGR of the market from 2025-2033?
◆ Which region dominates the global cancer immunotherapy industry?
Company Insights
Merck & Co., Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
AstraZeneca
Pfizer Inc.
Johnson & Johnson Services, Inc.
Novartis AG
Kite Pharma, Inc.
Dendreon Pharmaceuticals LLC
Amgen Inc.
Recent Developments:
April 2025 - Akeso, Inc. received NMPA approval in China for Ivonescimab, the world's first PD-1/VEGF bispecific antibody therapy for PD-L1-positive NSCLC patients.
September 2024 - F. Hoffmann-La Roche Ltd gained U.S. FDA approval for Tecentriq Hybreza, the first subcutaneous PD-L1 inhibitor approved in the United States.
September 2024 - Merck (MSD) obtained regulatory clearance in Japan for Keytruda to treat advanced non-small cell lung carcinoma and urothelial carcinoma.
Conclusion
The cancer immunotherapy market is poised for continued transformation as science and technology converge to advance precision medicine. Growing cancer prevalence worldwide, combined with breakthrough progress in immune checkpoint inhibitors and bispecific antibody development, is reinforcing the market's global footprint. With North America maintaining leadership and Asia-Pacific emerging as a key growth region, the next decade will mark a pivotal era in immuno-oncology, redefining cancer treatment standards and survival outcomes worldwide.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Immunotherapy Market Size to Reach US$ 261.74 Billion by 2033 at 7.9% CAGR here
News-ID: 4211860 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Europe Functional Bars Market to Reach US$ 450.1 Million by 2032 | Key Players: …
The Europe Functional Bars Market was valued at US$ 230.02 million in 2024 and is projected to reach US$ 450.1 million by 2032, growing at a CAGR of 8.75% during the forecast period 2025-2032, as per DataM intelligence research report
The Europe Functional Bars Market is driven by rising consumer demand for convenient, high-protein, and nutrient-rich snacks that support active and healthy lifestyles. Market growth is supported by increasing interest in…
Global AI Data Centers Market to Reach US$ 78.91 Billion by 2032 | Key Players: …
Leander, Texas and TOKYO, Japan - Nov 17 2025 "The Global AI Data Centers Market was valued at US$ 13.67 billion in 2024 and is projected to reach US$ 78.91 billion by 2032, growing at a CAGR of 24.50% during the forecast period 2025-2032."As per DataM intelligence research report.
The AI Data Centers Market is driven by the surging adoption of AI workloads that require high-performance computing, advanced storage, and accelerated…
United States Two-Component Polyurethane Foam Market to Reach $2.6 Billion by 20 …
Leander, Texas and TOKYO, Japan - Nov. 17, 2025. According to DataM Intelligence, the United States Two-Component Polyurethane Foam Market is expected to reach USD 2.6 billion by 2031, advancing at a CAGR of 7.4% as energy-efficient construction and insulation upgrades accelerate nationwide. Growing pressure to meet U.S. Department of Energy efficiency targets, alongside rising demand for lightweight, high-performance materials, is strengthening the adoption of two-component polyurethane systems across…
United States Ethylene-Vinyl Alcohol Copolymer Films Market to Reach $490 Millio …
Leander, Texas and TOKYO, Japan - Nov. 17, 2025. According to DataM Intelligence, the United States Ethylene-Vinyl Alcohol Copolymer (EVOH) Films Market is projected to reach USD 490 million by 2031, expanding at a steady 5.2% CAGR from USD 360 million in 2023, driven by accelerating demand for high-barrier packaging across food, pharmaceutical, and medical sectors. Renowned for exceptional oxygen and moisture barrier capabilities, EVOH films help brands extend shelf…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
